Medicare Part B coverage for CIDP is now available for Hizentra!*  

The convenience of self-infused Hizentra—covered under the same benefit category as IVIg.

CIDP Efficacy and Safety

Proven in the largest trial of CIDP and further evaluated in an extension study

First and Only FDA-Approved Subcutaneous Ig for CIDP maintenance
Largest Study in CIDP (n=172)

See the study design of PATH and
the Open-Label Extension (OLE) to PATH5,14

CIDP Pivotal Trial and Open-Label Extension Study Chart CIDP Pivotal Trial and Open-Label Extension Study Chart
PATH Pivotal Trial design: Data from a randomized, multicenter, double-blind, placebo-controlled, parallel-group, phase III study of 2 doses of weekly Hizentra versus placebo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)—the PATH Study. Subjects who relapsed during the postrandomized phase were to receive IVIg as a rescue medication within 1 week. CIDP relapse was defined as a ≥1-point increase in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) score compared with baseline. OLE to PATH Study design: 48-week, open-label, prospective extension study to PATH. 82 patients were enrolled: 62 patients were started on 0.4 g/kg weekly infusion of Hizentra, and 20 patients were started on 0.2 g/kg weekly. If clinically stable, patients on 0.4 g/kg were switched to 0.2 g/kg after 24 weeks. Upon CIDP relapse on 0.2 g/kg dose, 0.4 g/kg was either initiated or reinitiated. CIDP relapse defined as a ≥1-point increase in adjusted inflammatory Neuropathy Cause and Treatment (INCAT) score compared with baseline. Enrollment into the extension study started in 2014, more than 2 years after the start of the PATH study. Most patients had a time gap between completion of PATH and entry into the extension study during which they were treated with IVIG.

CIDP and the PATH study

Watch a summary of Dr. Jeffrey A. Allen's talk from the 2018 AANEM conference, where he discusses the PATH trial.



Frequently asked questions about Hizentra for CIDP

Want to know more about Hizentra? See answers to many prescribers' frequently asked questions.

Frequently asked questions about CIDP
Flexibility with Hizentra self-administration for CIDP

Create personalized treatment plans to meet your patients' clinical needs and personal preferences.

See why Hizentra may be right for your patients
acuity
You are now leaving the current website.

Do you want to continue?

No Yes